A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.

doi:10.1158/1078-0432.CCR-18-1881

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2019

Kurzrock Razelle, Ball Douglas W, Zahurak Marianna L, Nelkin Barry D, Subbiah Vivek, Ahmed Shabina, O'Connor Ashley, Karunsena Enusha, Parkinson Rose M, Bishop Justin A, Ha Yoonji, Sharma Rajni, Gocke Christopher D, Zinner Ralph, Rudek Michelle A, Sherman Steven I, Azad Nilofer S

Abstract excerpt

PURPOSE: Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals through RAS/RAF/MEK signaling. We evaluated the safety and efficacy of the VEGF receptor inhibitor pazopanib and MEK inhibitor trametinib in advanced solid tumors and DTC. PATIENTS AND METHODS: Patients with advanced solid tumors were enrolled in a phase I, multicenter trial with a DTC expansion cohort. Patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Pyridones

Share to Pyrimidines

Share to Pyrimidinones

Share to Receptors, Vascular Endothelial Growth Factor

Share to Sulfonamides

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 31186313
DOI: 10.1158/1078-0432.CCR-18-1881
PMCID: PMC7038784

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.PMID 31186313Read ↗

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Semantic proximity Read ↗

Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.Semantic proximity Read ↗

Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.Semantic proximity Read ↗

Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.Semantic proximity Read ↗

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Efficacy and Safety of targeted therapy Inhibitors for RET-driven Solid Cancer: A Systematic Review and Meta-analysisSemantic proximity Read ↗

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read ↗

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancerSemantic proximity Read ↗

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.